Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Rheumatology Drug Updates: Opioid CR845 for OA Pain; RA Treatments in Development

Michele B. Kaufman, PharmD, BCGP  |  March 15, 2016

CR845—an oral, peripherally selective kappa opioid agonist—is currently in Phase 2 trials for the treatment of pruritus, and acute and chronic pain.1 Eighty patients with hip osteoarthritis (OA) or knee OA were randomized to receive treatment with 0.25 mg, 0.5 mg, 1.0 mg or 5.0 mg CR845 twice daily for two weeks. Safety assessment, pharmacokinetics…

Filed under:AnalgesicsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:drugFDAopioidOsteoarthritisPainRheumatoid arthritisrheumatologySafetytrial

2015 ACR/ARHP Annual Meeting: Skin Issues in Rheumatic Diseases Present Challenges

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMeeting ReportsMyositisResearch RheumSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)dermatitisDermatologydermatomyositisDiagnosisImmunologyLupusResearchRheumatic DiseaseskinSLEsubacute cutaneous lupus erythematosus

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise

Michele B. Kaufman, PharmD, BCGP  |  March 2, 2016

Tofacitinib has been released from the FDA’s risk evaluation and mitigation strategy requirement. The FDA is also reviewing a biologics license application for ABP-501, an adalimumab biosimilar. And CHS-0214, a proposed etanercept biosimilar, has met its primary endpoint at Week 24 in an ongoing 52-week study…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabetanerceptFDAFood and Drug AdministrationTofacitinib

Hidradenitis Suppurativa Tied to Higher Mortality

David Douglas  |  February 24, 2016

NEW YORK (Reuters Health)—Hidradenitis suppurativa (HS) is associated with a significantly increased risk of adverse cardiovascular (CV) outcomes and all-cause mortality, according to Danish researchers. HS is a chronic, inflammatory skin disease and is most common in women. It is typically diagnosed after long delays, Dr. Alexander Egeberg of the University of Copenhagen and colleagues…

Filed under:ConditionsSystemic Sclerosis Tagged with:cardiovascularCardiovascular diseaseHidradenitis suppurativaPsoriasisskinskin inflammation

Apremilast Proves Effective for PsA with Skin Involvement

Michele B. Kaufman, PharmD, BCGP  |  February 24, 2016

A recent Phase 3 clinical trial found apremilast safe and effective for treating patients with active psoriatic arthritis and skin symptoms who found conventional and biologic DMARDs ineffective…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:apremilastPsoriasisPsoriatic Arthritisskin

Dermatology & Immunology: Skin Issues Can Present Challenges

Thomas R. Collins  |  February 23, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMyositisSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingDermatologydermatomyositisImmunologyLupusskin

Case Study in Dermatology: Tender Papules on Elbows, Hands in RA

Drew Kurtzman, MD, & Timothy McCalmont, MD, with Ruth Ann Vleugels, MD, MPH, & Joseph F. Merola, MD, MMSc  |  February 17, 2016

The Case A 41-year-old woman was referred to the dermatology clinic for a three-month history of tender lesions on her elbows and around the joints of her hands. Her medical history was notable for seropositive, non-erosive rheumatoid arthritis (RA), which was being treated with 5 mg pred­nisone daily, 10 mg methotrexate weekly by mouth, 200…

Filed under:ConditionsRheumatoid Arthritis Tagged with:case reportClinicalDermatologyDiagnosispapulespatient careRheumatoid arthritisrheumatologyTreatment

2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

Thomas R. Collins  |  February 16, 2016

SAN FRANCISCO—The risk of stroke after herpes zoster (HZ) infection is elevated in the period immediately after infection in patients with autoimmune diseases, according to a study presented at the 2015 ACR/ARHP Annual Meeting.1 The findings were presented in a scientific session, called Discover 2015, that highlighted new research. In another study from the session,…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)Autoimmune diseaseherpesInfectionpatient careResearchriskstroke

2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases

Susan Bernstein  |  February 16, 2016

SAN FRANCISCO—Metabolomics could one day be a treasure map of information about inflammation in rheumatic disease. There are many metabolic pathways to pursue for clues on how to reverse this damaging process. “All of these signaling pathways are interrelated and affect each other,” said Douglas J. Veale, MD, director of translational research at Dublin Academic…

Filed under:ConditionsMeeting ReportsOther Rheumatic ConditionsResearch Rheum Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)inflammationinflammatorymetabolicpathwaysResearchRheumatic Diseaserheumatologysignaling

Rheumatology Drug Updates: Biosimilars Seek Regulatory Approval in the U.S., Europe; Methotrexate Underused

Michele B. Kaufman, PharmD, BCGP  |  February 16, 2016

Biosimilars Receive Positive News On Nov. 19, 2015, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for SB4, an etanercept biosimilar product that will be called Benepali.1 If approved, Benepali can be used to treat rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis and plaque psoriasis….

Filed under:Biologics/DMARDsDrug Updates Tagged with:ApprovalsBiosimilarsdrugFDAIbuprofenMethotrexatepregabalinRheumatoid arthritisrheumatologySafetysarilumab

  • « Previous Page
  • 1
  • …
  • 40
  • 41
  • 42
  • 43
  • 44
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences